In case you missed our posts on Linked-In and Twitter yesterday, the Wall Street Journal is reporting big news in gene therapy and biopharma this wekend: WSJ reports that Roche is close to closing a deal to buy gene therapy company Spark Therapeutics (ONCE) for close to $5 billion. They claim that the deal could be announced Monday if not sooner. This would be a hefty price tag for Spark since it closed Friday with a market cap just under $2 billion and about $500 million in assets minus liabilities. This news should drive up small and mid-cap gene therapy stocks, at least some of which have been running higher this year already. In fact, this news will probably drive up small and mid-cap biopharma stocks in general since it continues the pace of recent multi-billion dollar acquisitions.
At Amp, the gene therapy stocks we follow, some of which are investments, have been running up this year. Check out our Amp Core holdings by becoming an Amp Core subscriber today, and you'll see the ONCE competitor that we like the most. Now with 30-day money-back guarantee. https://www.ampbioresearch.com/premium-plan